Schizophrenia Market Covers the Table of Contents With Segments, Key Players And Region. Based on
diagnosis, Schizophrenia Market is sub segmented into urine tests, brain imaging, vision testing, and
others. On the basis of treatment type, global Schizophrenia Market is classified surgery, radiation
therapy, medications, and others. Based on end user, Market is sub segmented into hospitals, clinics,
diagnostic centers, rehabilitation centers and others.
Regionally, The Americas dominate the global schizophrenia market owing to better treatment
availability, high healthcare expenditure, and increasing government support for research &
development. Europe holds the second position in the global schizophrenia market owing to the
government support for research & development and availability of funds for research.
Major Players profiled in the Schizophrenia Market report incorporate: Minerva Neurosciences (U.S.),
Promentis Pharmaceuticals, Inc. (U.S.), Bristol-Myers Squibb (U.S.), PsychoGenics Inc. (U.S.), Vineuro
Pharmaceuticals, Novartis AG (Switzerland), Merz Pharma GmbH & Co. KGaA (Germany), AbbVie Inc.
(U.S.), Eli-Lilly and Company (U.S.), AstraZeneca Plc (U.K)
Latest Industry News
Novartis has entered into a collaboration with Pear Therapeutics to develop novel prescription digital
therapeutics, software applications designed to effectively treat disease and improve clinical outcomes
for patients. The collaboration brings together Novartis expertise in biomedical research and clinical
development with Pear's leading experience in digital therapeutics design and implementation.
Novartis and Pear will work together towards developing new treatments for patients with
schizophrenia and multiple sclerosis to better address the full burden of their illnesses. Pear's
prescription digital therapeutics are designed to deliver clinically-proven treatments[1],[2], such as
cognitive behavioral therapy, to patients through mobile and desktop applications. Once approved, they
may be prescribed alongside drug therapies and have the potential to be developed to treat a range of
diseases.
Novartis will work with Pear to advance clinical development of their THRIVE(TM) digital therapeutic for
patients with schizophrenia. THRIVE(TM) has demonstrated potential usability, retention and
preliminary efficacy in patients with schizophrenia in early clinical studies.[3],[4],[5]. The companies will
also collaborate to design and develop a new therapeutic application to address underserved mental
health burden in patients with multiple sclerosis.
Request a Discount on standard prices of this premium report @
https://www.businessindustryreports.com/check-discount/162982 .
Region segment: This report is segmented into several key regions, with sales, revenue, market share
(%) and growth Rate (%) of Schizophrenia in these regions, from 2014 to 2023 (forecast), covering: North
America, Europe, Asia Pacific, Middle East & Africa and South America.
Significant points in table of contents: Market Definition, Market Overview, Business Introduction,
Segmentation (Region Level), Segmentation (Type Level), Segmentation (Industry Level), Segmentation